"versionIdentifier","uuid:ID","instanceType","rationale","id"
"2","0a73dcc1-f0db-4950-98d1-805471de492b","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1"
